Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events

Background: Although lenvatinib has become the standard therapy for hepatocellular carcinoma (HCC), the high incidence rate of adverse events (AEs) is an issue. This study aimed to clarify the AEs of lenvatinib and the therapeutic impact of five days-on/two days-off administration (i.e., weekends-of...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwamoto, Hideki, Suzuki, Hiroyuki, Shimose, Shigeo, Niizeki, Takashi, Nakano, Masahito, Shirono, Tomotake, Okamura, Shusuke, Noda, Yu, Kamachi, Naoki, Nakamura, Toru, Masuda, Atsutaka, Sakaue, Takahiko, Tanaka, Toshimitsu, Nakano, Dan, Sakai, Miwa, Yamaguchi, Taizo, Kuromatsu, Ryoko, Koga, Hironori, Torimura, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226076/
https://www.ncbi.nlm.nih.gov/pubmed/32325921
http://dx.doi.org/10.3390/cancers12041010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226076/
https://www.ncbi.nlm.nih.gov/pubmed/32325921
http://dx.doi.org/10.3390/cancers12041010

Ejemplares similares